
Telbivudine received regulatory approval in the United States from the Food and Drug Administration (FDA) in October 2006 for the treatment of CHB in adult patients with evidence of viral replication and active liver disease.
A product of Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), telbivudine is called TYZEKA® in the United States and is SEBIVO® in all other countries.
Find more details from the press release.






Comment Preview